The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression

被引:0
|
作者
Paxton, WA [1 ]
Kang, S [1 ]
Koup, RA [1 ]
机构
[1] Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purified CD4(+) lymphocytes of a group of highly exposed but HIV-1-uninfected individuals mere determined to be less susceptible to infection with multiple non-syncytium-inducing (NSI) primary isolates of HIV-1 than were CD4(+) lymphocytes from nonexposed control individuals. This relative resistance to HIV-1 infection did not extend to T cell line-adapted or syncytium-inducing (SI) primary viral isolates, mas restricted by the envelope glycoprotein, and was associated with an increased production of the C-C chemokines RANTES, MIP-1 alpha, and MIP-1 beta, The block to replication in CD4(+) lymphocytes from two exposed-uninfected subjects was at the point of entry, as was the block imposed by the recombinant C-C chemokines RANTES, MIP-1 alpha, and MIP-1 beta, Resistance to infection and the high production of beta chemokines were characteristic of every CD4(+) lymphocyte clone from the exposed-uninfected subjects. We have now identified the mechanism underlying this in vitro and in vivo resistance to infection: These individuals have inherited a homozygous 32-bp nucleotide deletion (Delta 32) within the gene encoding the coreceptor for primary NSI isolates of HIV-1 (CCR5), This deletion encodes a severely truncated and unstable protein that is not expressed on the cell surface. This allele is common in the Caucasian population, with a frequency of 0.0808, but is not found in people of African or Asian ancestry. To determine its role in HIV-1 transmission and disease progression, me analyzed the CCR5 genotype of 1252 homosexual men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS), No infected participant was found to be homozygous for the Delta 32 allele whereas 3.6% of at-risk but uninfected Caucasian participants were homozygous, showing the highly protective role of this genotype against sexual acquisition of HIV-1, No evidence was found to suggest that heterozygotes mere protected against HIV-1 infection, but a limited protective role against disease progression was noted. The Delta 32 allele of CCR5 is therefore an important host factor in HIV-1 transmission and pathogenesis.
引用
收藏
页码:S89 / S92
页数:4
相关论文
共 50 条
  • [11] CCR5 promoter polymorphism and HIV-1 disease progression
    McDermott, DH
    Zimmerman, PA
    Guignard, F
    Kleeberger, CA
    Leitman, SF
    Murphy, PM
    LANCET, 1998, 352 (9131): : 866 - 870
  • [12] Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression
    Li, M
    Song, RG
    Masciotra, S
    Soriano, V
    Spira, TJ
    Lal, RB
    Yang, CF
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (02) : 111 - 115
  • [13] Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression
    Esposito, S
    Zehender, G
    Zuccotti, GV
    Vegni, C
    Galli, L
    Vecchi, V
    Agostoni, C
    Rancilio, L
    De Maddalena, C
    Clerici, M
    Principi, N
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (09) : 847 - 849
  • [14] Heterozygous defect in HIV-1 coreceptor CCR5 and chemokine production
    Yang, JY
    Togni, M
    Widmer, U
    CYTOKINE, 1999, 11 (01) : 1 - 7
  • [15] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [16] Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor
    Espy, Nicole
    Pacheco, Beatriz
    Sodroski, Joseph
    VIROLOGY, 2017, 508 : 90 - 107
  • [17] CCR5 HIV-1 vertical transmission
    Shearer, WT
    Kalish, LA
    Zimmerman, PA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
  • [18] Viraemic control and viral coreceptor usage in two HIV-1-infected homozygous CCR5 Δ32 individuals
    Henrich, T.
    Hanhauser, E.
    Stellbrink, H-J
    Noah, C.
    Martin, J.
    Deeks, S.
    Kuritzkes, D.
    Pereyra, F.
    ANTIVIRAL THERAPY, 2013, 18 : A16 - A16
  • [19] Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32
    Henrich, Timothy J.
    Hanhauser, Emily
    Hu, Zixin
    Stellbrink, Hans-Juergen
    Noah, Christian
    Martin, Jeffrey N.
    Deeks, Steven G.
    Kuritzkes, Daniel R.
    Pereyra, Florencia
    AIDS, 2015, 29 (08) : 867 - 876
  • [20] Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry
    Moriuchi, H
    Moriuchi, M
    Fauci, AS
    JOURNAL OF IMMUNOLOGY, 1997, 159 (11): : 5441 - 5449